Trump authorizes convalescent plasma for COVID-19 treatment
United State’s President Donald Trump has made an historic announcement on the authorization of convalescent plasma to treat patients infected with the novel coronavirus.
Trump, during a press briefing at the White House said the Food and Drug Administration, a federal agency of the US Department of Health and Human Services, has authorized the emergency use of antibody-rich blood plasma from COVID-19 survivors to treat other coronavirus patients.
The FDA also noted in a press release on its website that based on the available scientific evidence, “the known and potential benefits of the product outweigh the known and potential risks of the product.”
“This is what I’ve been looking to do for a long time. This is a great thing,” Trump said.
“I’m pleased to make a truly historic announcement in our battle against the China virus that will save countless lives,” he added.
He continued that “The powerful therapy transfuses strong antibodies from the blood of recovered patients to help treat patients battling the infection.”
The FDA reiterated in its statement that over 70,000 American patients had been treated with convalescent plasma so far.
The US has reported nearly 5.7 million cases of the coronavirus, including around 2 million recoveries and over 176,700 deaths, according to figures compiled by US-based Johns Hopkins University.